Transplant Drug Improves Brain Blood Flow in Adults at Higher Alzheimer’s Risk, Study Finds
About This Article
University of Missouri researchers found that rapamycin improved blood flow to the brain in middle-aged adults with a genetic risk factor for Alzheimer’s disease. The early findings raise the possibility of future preventive treatments, although the drug has not been shown to prevent dementia.
Linda Kople
Linda Kople is a freelance writer focused on caregiving, aging, health, wellness, long-term care, and retirement planning
A drug used to prevent organ transplant rejection may hold promise for protecting the brain years before Alzheimer’s symptoms appear. Researchers at the University of Missouri found that low doses of rapamycin, also known as sirolimus, improved blood flow to the brain in middle-aged adults carrying a genetic variant associated with a higher risk of Alzheimer’s disease.
The findings offer a possible new direction for prevention research, but scientists caution that more testing is needed before the drug can be considered a treatment for people at risk of dementia.
How Did Rapamycin Affect Brain Blood Flow?
The study, published in the Journal of Cerebral Blood Flow & Metabolism, involved 23 adults aged 45 to 65 who had no signs of cognitive impairment. Nine participants carried the APOE4 gene variant, which increases the likelihood of developing Alzheimer's disease later in life. The other 14 did not carry the variant. All participants took 1 milligram of rapamycin daily for four weeks.
Brain imaging showed that participants carrying APOE4 experienced increases in blood flow exceeding 15 percent in several brain regions. Those without the variant showed no statistically significant change in overall brain blood flow.
Researchers also observed changes in certain metabolic and inflammatory markers, suggesting the drug may affect more than one biological process associated with brain health. Ai-Ling Lin, a professor at the University of Missouri School of Medicine and a senior author of the study, explained that researchers may be able to reduce the likelihood of developing Alzheimer’s disease.
Alzheimer’s tends to happen more in older people, especially for those with APOE4. If we can slow down aging in the brain for those people most at risk, researchers may be able to reduce their likelihood of developing Alzheimer’s disease." — Dr. Ai-Ling Lin.
Can Rapamycin Prevent Alzheimer’s Disease?
Researchers do not yet know whether rapamycin can prevent Alzheimer’s or delay the onset of dementia. The study was a small, four-week pilot trial without a randomized placebo-controlled comparison group. Researchers measured changes in brain circulation, not whether participants developed Alzheimer's disease.
Although blood flow improved among APOE4 carriers, the study did not establish improvements in memory or thinking. Researchers also found no significant changes in the Alzheimer's-related blood marker phosphorylated tau-217. Rapamycin is approved for certain medical uses, including preventing organ transplant rejection, but not for Alzheimer's prevention. The medication can suppress the immune system and cause serious side effects.
Larger clinical trials involving more diverse participants and longer follow-up periods will be necessary to determine whether improved circulation translates into lasting protection against cognitive decline.
What Could the Research Mean for Aging Adults?
Alzheimer's disease affects millions of older Americans and is a leading reason families eventually need help with supervision, personal care, and memory care services. As the disease progresses, people may need assistance with everyday activities, including bathing, dressing, eating, and managing medications. Family members often provide that care before professional long-term care services become necessary.
Finding ways to delay Alzheimer's symptoms could help people remain independent longer and potentially reduce the demands on family caregivers. For adults in their 40s, 50s and 60s, the Missouri research points toward a growing area of investigation: addressing changes in the brain before memory problems begin.
Rapamycin is not a proven way to prevent Alzheimer's, but the findings give researchers another possible approach to explore as they search for treatments that could delay the disease.
Medical Advances Offer Hope, but Planning for Aging Cannot Wait
Research into Alzheimer's disease, brain health and other conditions associated with aging will continue for decades. Scientists may discover new ways to delay cognitive decline, treat chronic illnesses, and help older adults maintain their independence longer.
However, medical breakthroughs take time, and there is no guarantee they will eliminate the need for long-term care. As Americans live longer, many will eventually need help with everyday activities because of chronic illness, dementia, mobility problems, or the physical effects of aging. The cost of that extended care continues to rise, whether it is provided at home, in assisted living, in memory care, or in a nursing home.
Medicare does not pay for ongoing custodial long-term care, and Medicaid assistance is primarily available to people who meet strict financial and care eligibility requirements. Families often face substantial out-of-pocket expenses, along with the physical and emotional demands of caregiving.
Medical research offers hope for a healthier future. But hope is not a financial plan. Preparing for the consequences of aging, including the rising cost of long-term care, remains one of the most important steps you can take to protect your savings, independence, and family.
Learn more about the impact of aging and extended lifespan, and the growing need for long-term care, with the resources available on LTC News. The LTC News Learning Center is a good first step.
If your family is already in crisis with a loved one with dementia or another age- or health-related need for long-term care, use the LTC News Caregiver Directory to search for caregivers and long-term care facilities nationwide.
If a loved one has a Long-Term Care Insurance policy, you can get free expert help with processing the LTC Insurance claim. LTC News partners with Amada Senior Care to provide free claim support with no cost or obligation — File a Long-Term Care Insurance Claim.
Frequently Asked Questions
Can rapamycin prevent or treat Alzheimer’s disease?
No clinical evidence currently establishes that rapamycin prevents or treats Alzheimer’s disease. Although researchers observed improved brain circulation, the study did not demonstrate better memory, improved thinking or a reduced likelihood of developing dementia. Larger, controlled clinical trials are needed.
Why could Alzheimer's prevention research matter for long-term care?
Alzheimer's disease can eventually make it difficult to manage medications, perform everyday activities or remain safe without supervision. Delaying the onset of dementia could potentially help older adults maintain independence longer and reduce caregiving demands. However, medical advances have not eliminated the need to plan for long-term care, including its rising costs. Medicare generally does not cover ongoing custodial care, making advance financial planning important for families.
What did the University of Missouri study discover about rapamycin?
Researchers found that rapamycin improved blood flow to several brain regions by more than 15 percent in adults carrying the APOE4 genetic variant, which is associated with a higher risk of Alzheimer’s disease. The small, four-week study involved 23 adults ages 45 to 65. The findings are preliminary and do not establish that the drug prevents dementia.
Is rapamycin safe for older adults to take for brain health?
Rapamycin, also called sirolimus, is approved for certain medical conditions, including preventing organ transplant rejection. It is not approved for Alzheimer's prevention. Because the medication suppresses immune function and can cause serious side effects, people should not take it for brain health outside appropriate medical supervision or clinical research.
What is the APOE4 gene, and does having it mean you will develop Alzheimer’s?
APOE4 is a genetic variant associated with an increased risk of developing Alzheimer’s disease, particularly later in life. However, carrying APOE4 does not mean someone will develop Alzheimer's. Many people with the variant never develop the disease, while others without it do. Genetics is one of several factors that influence Alzheimer's risk.
Sponsored
